Jazz Pharmaceuticals (NASDAQ: JAZZ) is a global biopharmaceutical company focused on neuroscience and oncology therapies. Shares recently traded around $173 per share, giving the company a market capitalization of roughly $10.3B.
After rebounding sharply over the past year, Jazz Pharmaceuticals now trades well above its prior lows, even as growth expectations remain moderate and leverage remains part of the investment narrative.
Looking at who owns Jazz Pharmaceuticals and how insiders have been trading helps show how large institutions and company leadership may be approaching the stock today.
Who Are Jazz Pharmaceuticals’ Top Shareholders?
Jazz Pharmaceuticals’ shareholder base is led by large institutional investors, particularly passive and long-only asset managers. These firms tend to hold through market cycles, which can help support ownership stability, while changes among active managers may reflect shifting views on valuation or near-term performance.
- The Vanguard Group: 5,882,899 shares (9.68%), ~$1.0B value. Reduced holdings by 184,810 shares (-3.05%).
- BlackRock Institutional Trust Company: 5,013,843 shares (8.25%), ~$852.4M value. Reduced holdings by 208,461 shares (-3.99%).
- Dimensional Fund Advisors: 2,836,652 shares (4.67%), ~$482.2M value. Added 298,815 shares (+11.77%).
- Capital World Investors: 2,554,867 shares (4.20%), ~$434.3M value. Added 10,345 shares (+0.41%).
- LSV Asset Management: 2,511,858 shares (4.13%), ~$427.0M value. Reduced holdings by 41,884 shares (-1.64%).
- State Street Investment Management (US): 1,867,886 shares (3.07%), ~$317.5M value. Reduced holdings by 67,499 shares (-3.49%).
- EcoR1 Capital: 1,706,469 shares (2.81%), ~$290.1M value. No reported quarter-over-quarter change.
- JPMorgan Asset Management: 1,701,555 shares (2.80%), ~$289.3M value. Added 152,322 shares (+9.83%).
- Fuller & Thaler Asset Management: 1,626,136 shares (2.68%), ~$276.4M value. Reduced holdings by 2,823 shares (-0.17%).
- Columbia Threadneedle Investments (US): 1,568,989 shares (2.58%), ~$266.7M value. Added 29,168 shares (+1.89%).
Ownership remains concentrated among long-term institutional holders, with trimming from some large passive managers balanced by selective buying from active firms, which for investors suggests steady core support alongside mixed views on near-term upside.
Hedge Fund Highlights
Balyasny Asset Management LP, founded by Dmitry Balyasny, increased its stake in Jazz Pharmaceuticals by 29.19% last quarter and now holds approximately $57.09M value of the stock. The increase suggests growing engagement following the stock’s recent recovery.
Schonfeld Strategic Advisors, founded by Steven Schonfeld, sharply expanded its Jazz position, boosting holdings by 592.11% to about $57.52M value. The move stands out among multi-strategy funds adding exposure during the period.
D. E. Shaw & Co., founded by David E. Shaw, raised its exposure to Jazz by 3,083.97%, bringing its position to roughly $16.39M value. While still a small allocation relative to firm size, the scale of the increase is notable.
Citadel Advisors, founded by Ken Griffin, increased its Jazz stake by 42.07% and now holds approximately $116.50M value in shares. The position remains a modest portion of Citadel’s portfolio, which for investors points to broad hedge fund interest rather than a single concentrated bet.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Jazz Pharmaceuticals’ Recent Insider Trades
Insider trades can offer context on how executives and directors may be managing personal exposure to the stock. Recent filings for Jazz Pharmaceuticals show multiple transactions, primarily clustered around mid-November.
- Bruce C. Cozadd (Director): Sold approximately 17,000 shares across multiple transactions between $180.09 and $182.60; also recorded 2,506 shares at $0.
- Heather Ann McSharry (Director): Sold 3,415 shares at $177.78; acquired 3,415 shares at $138.08.
- Mary Elizabeth Henderson (Officer): Sold 1,331 shares at $180.40.
- Rick E. Winningham (Director): Sold 5,500 shares at $180.86.
- Patricia Carr (Officer): Sold 5,250 shares at $182.07; acquired 5,250 shares at $136.18; sold 69 shares at $181.66.
It appears insider activity leans toward selling at prices near recent highs, with some offsetting acquisitions at lower levels, which for investors provides context but does not materially alter overall ownership.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
Jazz Pharmaceuticals’ shareholder base remains anchored by large institutional investors, even as some passive managers trimmed positions. Hedge fund activity has skewed toward adding exposure, while insider trades appear measured following the stock’s rally.
For investors, this combination suggests balanced sentiment, with institutional support intact but positioning reflecting caution as the company navigates moderate growth expectations, leverage considerations, and a share price that has already moved meaningfully higher.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
